{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pre-filled+syringe+%28PFS%29", "query": { "intervention": "Pre-filled syringe (PFS)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 59, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pre-filled+syringe+%28PFS%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-25T08:12:18.159Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05774639", "title": "Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Idiopathic Urticaria" ], "interventions": [ { "name": "Omalizumab Injection", "type": "DRUG" }, { "name": "Xolair Prefilled Syringe", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kashiv BioSciences, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 600, "start_date": "2023-08-15", "completion_date": "2024-12-31", "has_results": false, "last_update_posted_date": "2025-02-05", "last_synced_at": "2026-09-25T08:12:18.159Z", "location_count": 4, "location_summary": "Brandon, Florida • Brooksville, Florida • Miami Lakes, Florida + 1 more", "locations": [ { "city": "Brandon", "state": "Florida" }, { "city": "Brooksville", "state": "Florida" }, { "city": "Miami Lakes", "state": "Florida" }, { "city": "West Lafayette", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05774639" }, { "nct_id": "NCT04333147", "title": "Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthritis, Rheumatoid" ], "interventions": [ { "name": "Otilimab (GSK3196165)", "type": "BIOLOGICAL" }, { "name": "csDMARD(s)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2916, "start_date": "2020-05-12", "completion_date": "2023-02-24", "has_results": true, "last_update_posted_date": "2024-02-07", "last_synced_at": "2026-09-25T08:12:18.159Z", "location_count": 79, "location_summary": "Anniston, Alabama • Flagstaff, Arizona • Gilbert, Arizona + 63 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Flagstaff", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04333147" }, { "nct_id": "NCT01462318", "title": "An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsing-Remitting Multiple Sclerosis" ], "interventions": [ { "name": "Midazolam", "type": "DRUG" }, { "name": "Caffeine", "type": "OTHER" }, { "name": "S-warfarin", "type": "DRUG" }, { "name": "Vitamin K", "type": "OTHER" }, { "name": "Omeprazole", "type": "DRUG" }, { "name": "Dextromethorphan", "type": "DRUG" }, { "name": "BIIB019 (Daclizumab)", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 133, "start_date": "2011-11", "completion_date": "2016-01", "has_results": true, "last_update_posted_date": "2017-03-14", "last_synced_at": "2026-09-25T08:12:18.159Z", "location_count": 7, "location_summary": "Centennial, Colorado • Washington D.C., District of Columbia • Lake Barrington, Illinois + 4 more", "locations": [ { "city": "Centennial", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Lake Barrington", "state": "Illinois" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Farmington Hills", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01462318" }, { "nct_id": "NCT01356602", "title": "Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Gouty Arthritis" ], "interventions": [ { "name": "Canakinumab pre-filled syringe", "type": "DRUG" }, { "name": "Canakinumab lyophilized powder", "type": "DRUG" }, { "name": "Triamcinolone Acetonide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 397, "start_date": "2011-05", "completion_date": "2012-09", "has_results": true, "last_update_posted_date": "2014-01-29", "last_synced_at": "2026-09-25T08:12:18.159Z", "location_count": 69, "location_summary": "Anniston, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 62 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Gulf Shores", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01356602" }, { "nct_id": "NCT06708637", "title": "Ocular Safety and Usability Study for FYB203 PFS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Age-Related Macular Degeneration", "Branch Retinal Vein Occlusion with Macular Edema", "Central Retinal Vein Occlusion with Macular Edema", "Diabetic Macular Edema", "Diabetic Retinopathy" ], "interventions": [ { "name": "FYB203 2 mg (0.05 mL of 40 mg/mL)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Formycon AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2024-09-20", "completion_date": "2024-10-08", "has_results": false, "last_update_posted_date": "2024-11-27", "last_synced_at": "2026-09-25T08:12:18.159Z", "location_count": 4, "location_summary": "Campbell, California • Long Beach, California • Redlands, California + 1 more", "locations": [ { "city": "Campbell", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Redlands", "state": "California" }, { "city": "Eugene", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT06708637" }, { "nct_id": "NCT01578785", "title": "An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsing-Remitting Multiple Sclerosis" ], "interventions": [ { "name": "Glatiramer Acetate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 178, "start_date": "2012-03", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2014-04-02", "last_synced_at": "2026-09-25T08:12:18.159Z", "location_count": 25, "location_summary": "Cullman, Alabama • Fresno, California • La Jolla, California + 17 more", "locations": [ { "city": "Cullman", "state": "Alabama" }, { "city": "Fresno", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Centennial", "state": "Colorado" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01578785" }, { "nct_id": "NCT03926169", "title": "A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hidradenitis Suppurativa" ], "interventions": [ { "name": "Risankizumab", "type": "DRUG" }, { "name": "Placebo for risankizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 243, "start_date": "2019-06-03", "completion_date": "2021-08-02", "has_results": true, "last_update_posted_date": "2022-08-11", "last_synced_at": "2026-09-25T08:12:18.159Z", "location_count": 22, "location_summary": "Hot Springs, Arkansas • Bakersfield, California • Los Angeles, California + 17 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03926169" }, { "nct_id": "NCT04840901", "title": "A Study of Lebrikizumab (LY3650150) Administered by Two Different Devices in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Lebrikizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 242, "start_date": "2021-06-02", "completion_date": "2022-02-11", "has_results": true, "last_update_posted_date": "2024-11-22", "last_synced_at": "2026-09-25T08:12:18.159Z", "location_count": 4, "location_summary": "Daytona Beach, Florida • Springfield, Missouri • Dallas, Texas + 1 more", "locations": [ { "city": "Daytona Beach", "state": "Florida" }, { "city": "Springfield", "state": "Missouri" }, { "city": "Dallas", "state": "Texas" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04840901" }, { "nct_id": "NCT01431638", "title": "Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Gouty Arthritis" ], "interventions": [ { "name": "Canakinumab 150mg in prefilled syringe", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 397, "start_date": "2011-08-25", "completion_date": "2013-05-09", "has_results": true, "last_update_posted_date": "2021-07-19", "last_synced_at": "2026-09-25T08:12:18.159Z", "location_count": 54, "location_summary": "Anniston, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 50 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Gulf Shores", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01431638" }, { "nct_id": "NCT03099980", "title": "Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Hidradenitis Suppurativa" ], "interventions": [ { "name": "secukinumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Tufts Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2016-07-11", "completion_date": "2019-01", "has_results": false, "last_update_posted_date": "2019-06-03", "last_synced_at": "2026-09-25T08:12:18.159Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03099980" } ] }